{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"REZILIENT4","nct_id":"NCT07128199","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=rezilient4-nct07128199. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"REZILIENT4","arms":[{"description":"Participants will receive zipalertinib orally until the participant meets any of the treatment discontinuation criteria.","label":"Zipalertinib","type":"EXPERIMENTAL"},{"description":"Participants will receive zipalertinib matching-placebo, until the participant meets any of the treatment discontinuation criteria.","label":"Placebo","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2032-10-01","type":"ESTIMATED"},"conditions":["Lung Cancer","Adjuvant","Post-surgical","EGFR","Exon 20","Early Stage Lung Cancer","Uncommon EGFR Mutations","NSCLC, Early Stage"],"enrollment":{"count":360,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"TAS6417","otherNames":["Zipalertinib","CLN-081"],"type":"DRUG"},{"name":"Zipalertinib Matching-placebo","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-13","lead_sponsor":"Taiho Oncology, Inc.","official_title":"A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Versus Placebo in Early Stage NSCLC Patients With Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-10-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Disease-free Survival (DFS) as Assessed by the Investigator","timeFrame":"Up to 5 years"}],"references":[],"start_date":{"date":"2025-12-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection","url":"https://clinicaltrials.gov/study/NCT07128199"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/rezilient4-nct07128199"}